BUKO Pharma-Kampagne and IPH Bangalore have made a survey of the business behavior of Bayer Health Care, Boehringer Ingelheim and Baxter in India. The results: these companies sell many irrational preparations and offer only few essential innovations. Bayer and Boehringer Ingelheim conduct numerous clinical trials in India, but they prefer to search for new applications of their blockbusters instead of doing research in the field of neglected diseases. Especially Boehringer Ingelheim has a poor pharmaceutical portfolio with 70% of irrational drugs and no essential preparation. On the other hand, the company renounce to strictly assume their patent rights in the case of nevirapine. This important Aids drug
can therefore be generically produced in India at a low price, which ensures access to this drug for poor countries, in particular in southern Africa. Whereas 64% of Bayer products sold in India are rational, the aggressive patent policy of that German company blocks access to the innovative cancer drug sorafenib (Nexavar®). The company Baxter has a quite good product portfolio with 88% of rational products including 44% of essential drugs. But many of those products do not have a generic alternative in India. Their price is high and excludes the poor from access.